Mycobacterium keratitis following hyperopic laser in situ keratomileusis.
Suresh
P S
PS
Department of Ophthalmology, Toronto Western Hospital, Ont.
Campbell
I
I
Herzig
S
S
Rootman
D S
DS
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003315:Cornea / Q000382:microbiology* / Q000601:surgery; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D015818:Eye Infections, Bacterial / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D006801:Humans; D006956:Hyperopia / Q000601:surgery*; D007634:Keratitis / Q000188:drug therapy / Q000209:etiology*; D020731:Keratomileusis, Laser In Situ / Q000009:adverse effects*; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy / Q000209:etiology*; D016926:Mycobacterium chelonae / Q000302:isolation & purification*; D011239:Prednisolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014031:Tobramycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; C009022:prednisolone phosphate; D011239:Prednisolone; D014031:Tobramycin